Letter: Persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 5, 2012, Pages 499-500

  Steenholdt, C ^a   Brynskov, J ^a   Bendtzen, K ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB; INFLIXIMAB ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; CROHN DISEASE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; LETTER; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SAMPLE SIZE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864654703     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05204.x     Document Type: Letter

References (8)

1. Ben-Horin S, Mazor Y, Yanai H, et al,. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting reinduction outcome in IBD. Aliment Pharmacol Ther 2012; 35: 714-22.
2. Steenholdt C, Al-Khalaf M, Brynskov J, Bendtzen K, Thomsen OO, Ainsworth MA,. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012 [Epub ahead of print].
3. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T,. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9.
4. Ainsworth MA, Bendtzen K, Brynskov J,. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-8.
5. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA,. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-8.
6. Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA,. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis 2012; 6: 108-11.
7. Steenholdt C, Svenson M, Ainsworth MA, Thomsen OO, Brynskov J, Bendtzen K,. Comparison of techniques for monitoring infliximab bioavailability and immunogenicity in Crohn's disease. Gastroenterology 2012; 142 (Suppl.1): S-781.
8. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.